CA1329119C
(en)
*
|
1988-03-29 |
1994-05-03 |
Milton David Goldenberg |
Cytotoxic therapy
|
US5439665A
(en)
*
|
1988-07-29 |
1995-08-08 |
Immunomedics |
Detection and treatment of infectious and inflammatory lesions
|
US4925648A
(en)
*
|
1988-07-29 |
1990-05-15 |
Immunomedics, Inc. |
Detection and treatment of infectious and inflammatory lesions
|
US5601819A
(en)
*
|
1988-08-11 |
1997-02-11 |
The General Hospital Corporation |
Bispecific antibodies for selective immune regulation and for selective immune cell binding
|
JPH04504248A
(ja)
*
|
1988-09-30 |
1992-07-30 |
ネオロクス コーポレーション |
シッフ塩基で結合した、ターゲティング物質―診断/治療薬複合体
|
US5066789A
(en)
*
|
1988-09-30 |
1991-11-19 |
Neorx Corporation |
Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
|
US4986979A
(en)
*
|
1989-03-14 |
1991-01-22 |
Neorx Corporation |
Imaging tissue sites of inflammation
|
CA1339415C
(en)
*
|
1989-08-24 |
1997-09-02 |
Milton David Goldenberg |
Detection and treatment of infections with immunoconjugates
|
US5332567A
(en)
|
1989-08-24 |
1994-07-26 |
Immunomedics |
Detection and treatment of infections with immunoconjugates
|
AU6290090A
(en)
*
|
1989-08-29 |
1991-04-08 |
University Of Southampton |
Bi-or trispecific (fab)3 or (fab)4 conjugates
|
KR0162259B1
(ko)
*
|
1989-12-05 |
1998-12-01 |
아미 펙터 |
감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
|
US5079343A
(en)
*
|
1990-01-05 |
1992-01-07 |
Dana-Farber Cancer Institute, Inc. |
Intracellular antigen found in subpopulation of cd8+ t lymphocytes and monoclonal antibody reactive with same
|
US5340935A
(en)
*
|
1990-01-05 |
1994-08-23 |
Dana-Farber Cancer Institute, Inc. |
DNAS encoding proteins active in lymphocyte-medicated cytotoxicity
|
US5368840A
(en)
*
|
1990-04-10 |
1994-11-29 |
Imarx Pharmaceutical Corp. |
Natural polymers as contrast media for magnetic resonance imaging
|
ES2138122T3
(es)
*
|
1990-04-10 |
2000-01-01 |
Imarx Pharmaceutical Corp |
Polimeros como medios de contraste para resonancia magnetica.
|
DK176290D0
(da)
*
|
1990-07-24 |
1990-07-24 |
Novo Nordisk As |
Terapeutisk og diagnostisk praeparat
|
US5277892A
(en)
*
|
1990-08-08 |
1994-01-11 |
Rhomed Incorporated |
In vivo lymphocyte tagging
|
US5223241A
(en)
*
|
1990-10-01 |
1993-06-29 |
The General Hospital Corporation |
Method for early detection of allograft rejection
|
EP0485664A1
(en)
*
|
1990-11-13 |
1992-05-20 |
Mallinckrodt Diagnostica (Holland) B.V. |
Method of preparing a diagnostic agent for detecting inflammations
|
CA2065658A1
(en)
*
|
1991-04-19 |
1992-10-20 |
Tse-Wen Chang |
Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
|
US6106835A
(en)
*
|
1991-04-19 |
2000-08-22 |
Tanox, Inc. |
Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators
|
US5401489A
(en)
*
|
1991-05-01 |
1995-03-28 |
University Of New Mexico |
Biomodulators as universal imaging agents
|
WO1992019264A1
(en)
*
|
1991-05-01 |
1992-11-12 |
University Of New Mexico |
Biomodulators as universal imaging agents
|
US5240693A
(en)
*
|
1991-05-01 |
1993-08-31 |
University Of New Mexico |
Image enhancement by coadministration of biomodulators and structurally modified imaging agents
|
US5364612A
(en)
*
|
1991-05-06 |
1994-11-15 |
Immunomedics, Inc. |
Detection of cardiovascular lesions
|
DE4140142A1
(de)
*
|
1991-12-05 |
1993-06-09 |
Boehringer Mannheim Gmbh, 6800 Mannheim, De |
Multivalentes dextranreagenz zum einsatz in praezipitationstests
|
US5248772A
(en)
*
|
1992-01-29 |
1993-09-28 |
Coulter Corporation |
Formation of colloidal metal dispersions using aminodextrans as reductants and protective agents
|
US5643549A
(en)
*
|
1992-02-20 |
1997-07-01 |
Rhomed Incorporated |
Leukostimulatory agent for in vivo leukocyte tagging
|
US5508020A
(en)
|
1992-06-05 |
1996-04-16 |
Diatech, Inc. |
Technetium-99M labeled peptides for imaging
|
US6096289A
(en)
*
|
1992-05-06 |
2000-08-01 |
Immunomedics, Inc. |
Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
|
US6228362B1
(en)
|
1992-08-21 |
2001-05-08 |
Immunomedics, Inc. |
Boron neutron capture therapy using pre-targeting methods
|
GB9225448D0
(en)
*
|
1992-12-04 |
1993-01-27 |
Erba Carlo Spa |
Improved synthesis of polymer bioactive conjugates
|
US5648218A
(en)
*
|
1993-02-12 |
1997-07-15 |
Sealite Sciences, Inc. |
Preparation of photoprotein conjugates and methods of use thereof
|
AU6171894A
(en)
*
|
1993-02-12 |
1994-08-29 |
Sealite Sciences, Inc. |
Preparation of photoprotein conjugates and methods of use thereof
|
US5951964A
(en)
*
|
1993-06-04 |
1999-09-14 |
Diatide, Inc. |
Technetium-99m labeled peptides for imaging
|
AU6920194A
(en)
*
|
1993-06-11 |
1995-01-03 |
Coulter Corporation |
Anti-cd3 antibody-aminodextran conjugates for induction of t-cell activation and proliferation
|
US7597886B2
(en)
*
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7820798B2
(en)
*
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US7964190B2
(en)
*
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
US5891741A
(en)
*
|
1997-05-16 |
1999-04-06 |
Coulter International Corp. |
Antibody-aminodextran-phycobiliprotein conjugates
|
EP1034003A4
(en)
|
1997-11-24 |
2004-07-14 |
Johnson T Wong |
METHODS FOR TREATING HIV OR OTHER INFECTIONS USING A T CELL ACTIVATOR OR A VIRAL ACTIVATOR AND ANTIRETROVIRAL COMBINATION THERAPY
|
EP1093457B8
(en)
|
1998-03-19 |
2011-02-02 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
DE69942565D1
(de)
|
1998-05-20 |
2010-08-19 |
Immunomedics Inc |
Therapeutische mittel welche einen bispezifischen anti-hla class ii invariant chain x anti-pathogen antikörper enthalten
|
CA2363779A1
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
US7291714B1
(en)
*
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
US20040001826A1
(en)
*
|
1999-06-30 |
2004-01-01 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
US20030171267A1
(en)
|
2000-04-12 |
2003-09-11 |
Rosen Craig A. |
Albumin fusion proteins
|
US7700359B2
(en)
*
|
2000-06-02 |
2010-04-20 |
Novartis Vaccines And Diagnostics, Inc. |
Gene products differentially expressed in cancerous cells
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
AU2001282856A1
(en)
|
2000-06-15 |
2001-12-24 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
ES2609016T3
(es)
|
2000-06-16 |
2017-04-18 |
Human Genome Sciences, Inc. |
Anticuerpos que se unen inmunoespecíficamente a BLyS
|
AU1994402A
(en)
|
2000-11-28 |
2002-06-11 |
Mediummune Inc |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
US20040018194A1
(en)
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
EP2354149B1
(en)
|
2000-12-12 |
2017-08-30 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
EP1683865A3
(en)
|
2001-02-02 |
2006-10-25 |
Eli Lilly & Company |
Mammalian proteins and in particular CD200
|
EP1366058B1
(en)
|
2001-02-09 |
2011-01-26 |
Human Genome Sciences, Inc. |
Human g-protein chemokine receptor (ccr5) hdgnr10
|
WO2002098370A2
(en)
*
|
2001-03-02 |
2002-12-12 |
Medimmune, Inc. |
Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
|
SE0100728D0
(sv)
*
|
2001-03-05 |
2001-03-05 |
Sidec Technologies Ab Karolins |
New method
|
US7208582B2
(en)
|
2001-04-13 |
2007-04-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
US20070015144A9
(en)
*
|
2001-05-25 |
2007-01-18 |
Genset, S.A. |
Human cDNAs and proteins and uses thereof
|
US6867189B2
(en)
*
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
EP1997829A1
(en)
|
2001-12-21 |
2008-12-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
JP4376629B2
(ja)
*
|
2002-01-08 |
2009-12-02 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
癌性胸部細胞において差次的に発現された遺伝子産物およびその使用方法
|
AU2003209340A1
(en)
*
|
2002-01-18 |
2003-09-02 |
Bristol-Myers Squibb Company |
Predictor sets for tyrosine kinase pathways
|
EP1483682A2
(de)
|
2002-01-19 |
2004-12-08 |
PACT XPP Technologies AG |
Reconfigurierbarer prozessor
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
US8877901B2
(en)
|
2002-12-13 |
2014-11-04 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
DK3483183T3
(da)
|
2002-03-01 |
2021-06-21 |
Immunomedics Inc |
Immunokonjugat omfattende humaniserede rs7-antistoffer
|
JP2005533001A
(ja)
*
|
2002-03-04 |
2005-11-04 |
メディミューン,インコーポレーテッド |
インテグリンαvβ3アンタゴニストを他の物質と併用投与する癌の予防または治療方法
|
EP1499352A4
(en)
|
2002-04-12 |
2006-10-11 |
Medimmune Inc |
ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
|
US20050176068A1
(en)
*
|
2002-04-26 |
2005-08-11 |
Emmert-Buck Michael R. |
Direct cell target analysis
|
EP1531848A4
(en)
*
|
2002-06-10 |
2007-03-28 |
Vaccinex Inc |
DIFFERENTIAL EXPRESSED GENE IN BREAST AND BLADDER CANCER AND CODED POLYPEPTIDE
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
JP5139626B2
(ja)
|
2002-06-14 |
2013-02-06 |
イミューノメディクス、インコーポレイテッド |
モノクローナル抗体hPAM4
|
EP1534335B9
(en)
|
2002-08-14 |
2016-01-13 |
Macrogenics, Inc. |
Fcgammariib-specific antibodies and methods of use thereof
|
JP4596916B2
(ja)
*
|
2002-09-05 |
2010-12-15 |
メディミューン,エルエルシー |
Cd2拮抗薬を投与することによりt細胞悪性腫瘍を予防または治療する方法
|
US7939304B2
(en)
*
|
2002-10-02 |
2011-05-10 |
Catalyst Biosciences, Inc. |
Mutant MT-SP1 proteases with altered substrate specificity or activity
|
US20060024289A1
(en)
*
|
2002-10-02 |
2006-02-02 |
Ruggles Sandra W |
Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
|
PT2891666T
(pt)
|
2002-10-16 |
2017-09-22 |
Purdue Pharma Lp |
Anticorpos que se ligam ca 125/0722p associado a células e métodos para a sua utilização
|
US7651689B2
(en)
*
|
2002-11-15 |
2010-01-26 |
Albert Einstein College Of Medicine Of Yeshiva University |
Methods of applying ionization radiation for therapy of infections
|
AU2004204494B2
(en)
|
2003-01-09 |
2011-09-29 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
EP1585815A4
(en)
*
|
2003-01-21 |
2006-02-22 |
Bristol Myers Squibb Co |
A NEW ACYL-COENZYME A, MONOCLYLGLYCERIN ACYLTRANSFERASE-3 (MGAT3), CODING POLYNUCLEOTIDE, AND USES THEREOF
|
US7695752B2
(en)
*
|
2003-01-24 |
2010-04-13 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target activated microtransfer
|
US7709047B2
(en)
*
|
2003-01-24 |
2010-05-04 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target activated microtransfer
|
ES2347959T3
(es)
|
2003-02-20 |
2010-11-26 |
Seattle Genetics, Inc. |
Conjugados de anticuerpos anti-cd70-farmaco y su uso para el tratamiento del cancer.
|
EP1613273B1
(en)
|
2003-04-11 |
2012-06-13 |
MedImmune, LLC |
Recombinant il-9 antibodies and uses thereof
|
US20070065887A1
(en)
*
|
2003-07-21 |
2007-03-22 |
Kinch Michael S |
Diagnosis of pre-cancerous conditions using pcdgf agents
|
CA2534898A1
(en)
*
|
2003-08-08 |
2005-02-17 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
JP5042631B2
(ja)
*
|
2003-12-04 |
2012-10-03 |
バクシネックス インコーポレーティッド |
アポトーシス腫瘍細胞上に露出した細胞内抗原をターゲッティングすることによって腫瘍細胞を死滅させる方法
|
US7371381B2
(en)
*
|
2003-12-12 |
2008-05-13 |
Amgen Inc. |
Anti-galanin antibodies and uses thereof
|
SI1703893T1
(sl)
|
2003-12-23 |
2012-07-31 |
Genentech Inc |
Nova protitelesa proti il in uporaba le teh
|
HUE027902T2
(en)
|
2004-02-09 |
2016-11-28 |
Human Genome Sciences Inc Corp Service Company |
Albumin fusion proteins
|
CN107988363A
(zh)
|
2004-03-31 |
2018-05-04 |
综合医院公司 |
测定癌症对表皮生长因子受体靶向性治疗反应性的方法
|
CA2562729C
(en)
*
|
2004-04-12 |
2013-11-12 |
Sandra Waugh Ruggles |
Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1
|
WO2006017673A2
(en)
|
2004-08-03 |
2006-02-16 |
Biogen Idec Ma Inc. |
Taj in neuronal function
|
JP2008513540A
(ja)
|
2004-09-21 |
2008-05-01 |
メディミューン,インコーポレーテッド |
呼吸器合胞体ウイルスに対する抗体及び該ウイルス用のワクチンを製造する方法
|
AU2005299355A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Llc |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
EP1661584A1
(en)
*
|
2004-11-26 |
2006-05-31 |
Heinz Dr. Faulstich |
Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
|
US20070014795A1
(en)
*
|
2004-12-30 |
2007-01-18 |
Dhodapkar Madhav V |
Compositions and methods for enhanced dendritic cell maturation and function
|
KR101335798B1
(ko)
|
2005-02-15 |
2013-12-02 |
듀크 유니버시티 |
항-cd19 항체 및 종양학에서 이의 용도
|
WO2006110214A2
(en)
*
|
2005-04-08 |
2006-10-19 |
Medimmune, Inc. |
Antibodies against mammalian metapneumovirus
|
US20060269556A1
(en)
*
|
2005-04-18 |
2006-11-30 |
Karl Nocka |
Mast cell activation using siglec 6 antibodies
|
EP2511299A1
(en)
|
2005-04-19 |
2012-10-17 |
Seattle Genetics, Inc. |
Humanized anti-CD70 binding agents and uses thereof
|
CA2607281C
(en)
|
2005-05-05 |
2023-10-03 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
EP2301969B1
(en)
|
2005-05-06 |
2015-12-23 |
ZymoGenetics, Inc. |
IL-31 monoclonal antibodies and methods of use
|
WO2007002543A2
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
EP1904652A2
(en)
*
|
2005-07-08 |
2008-04-02 |
Brystol-Myers Squibb Company |
Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
|
SG163591A1
(en)
|
2005-07-08 |
2010-08-30 |
Biogen Idec Inc |
Sp35 antibodies and uses thereof
|
EP1920057A4
(en)
|
2005-08-03 |
2009-03-18 |
Grains Res & Dev Corp |
POLYSACCHARIDE synthases
|
SI1919503T1
(sl)
|
2005-08-10 |
2015-02-27 |
Macrogenics, Inc. |
Identifikacija in inĺ˝eniring protiteles z variantnimi fc regijami in postopki za njih uporabo
|
US20070202512A1
(en)
*
|
2005-08-19 |
2007-08-30 |
Bristol-Myers Squibb Company |
Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
|
US7957466B2
(en)
*
|
2005-09-16 |
2011-06-07 |
Sony Corporation |
Adaptive area of influence filter for moving object boundaries
|
US7422899B2
(en)
|
2005-10-05 |
2008-09-09 |
Biogen Idec Ma Inc. |
Antibodies to the human prolactin receptor
|
JP5905184B2
(ja)
|
2005-10-13 |
2016-04-20 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッドHuman Genome Sciences, Inc. |
自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
|
EP2500030B2
(en)
|
2005-11-04 |
2018-08-08 |
Genentech, Inc. |
Use of complement pathway inhibitors to treat ocular diseases
|
EP1945261A4
(en)
|
2005-11-07 |
2010-05-12 |
Scripps Research Inst |
COMPOSITIONS AND METHODS FOR CONTROLLING THE SPECIFICITY OF TISSUE FACTOR SIGNALING
|
US20070136826A1
(en)
*
|
2005-12-02 |
2007-06-14 |
Biogen Idec Inc. |
Anti-mouse CD20 antibodies and uses thereof
|
DOP2006000277A
(es)
|
2005-12-12 |
2007-08-31 |
Bayer Pharmaceuticals Corp |
Anticuerpos anti mn y métodos para su utilización
|
US8389688B2
(en)
|
2006-03-06 |
2013-03-05 |
Aeres Biomedical, Ltd. |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
ES2371085T3
(es)
*
|
2006-05-27 |
2011-12-27 |
Faulstich, Heinz, Dr. |
Utilización de conjugados de amatoxinas o falotoxinas con macromoléculas para la terapia tumoral y de la inflamación.
|
US7910108B2
(en)
*
|
2006-06-05 |
2011-03-22 |
Incyte Corporation |
Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
|
BRPI0713426A2
(pt)
|
2006-06-14 |
2012-10-09 |
Macrogenics Inc |
métodos de tratar, diminuir a progressão, ou melhorar um ou mais sintomas de um distúrbio, e de prevenir ou retardar o inìcio de um distúrbio
|
CA2656918A1
(en)
*
|
2006-06-22 |
2007-12-27 |
Vaccinex, Inc. |
Anti-c35 antibodies for treating cancer
|
PL2029173T3
(pl)
|
2006-06-26 |
2017-04-28 |
Macrogenics, Inc. |
Przeciwciała swoiste dla FC RIIB i sposoby ich zastosowania
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
EP2046951B1
(en)
|
2006-07-05 |
2011-10-26 |
Catalyst Biosciences, Inc. |
Protease screening methods and proteases identified thererby
|
CN103044550A
(zh)
|
2006-09-01 |
2013-04-17 |
津莫吉尼蒂克斯公司 |
Il-31单克隆抗体的可变区序列和使用方法
|
EP2354254A1
(en)
|
2006-09-06 |
2011-08-10 |
Ortho-McNeil Pharmaceutical, Inc. |
Biomarkers for assessing response to C-met treatment
|
JP2010506842A
(ja)
|
2006-10-16 |
2010-03-04 |
メディミューン,エルエルシー |
半減期が短縮された分子、その組成物および使用
|
EP2609932B1
(en)
|
2006-12-01 |
2022-02-02 |
Seagen Inc. |
Variant target binding agents and uses thereof
|
NZ577274A
(en)
|
2006-12-18 |
2012-10-26 |
Genentech Inc |
Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
|
PT2068887E
(pt)
|
2007-01-09 |
2014-06-23 |
Biogen Idec Inc |
Anticorpos sp35 e suas utilizações
|
WO2008118324A2
(en)
|
2007-03-26 |
2008-10-02 |
Macrogenics, Inc. |
Composition and method of treating cancer with an anti-uroplakin ib antibody
|
US7807168B2
(en)
*
|
2007-04-10 |
2010-10-05 |
Vaccinex, Inc. |
Selection of human TNFα specific antibodies
|
EP2737907A3
(en)
|
2007-05-07 |
2014-11-05 |
MedImmune, LLC |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
DK3072525T3
(da)
|
2007-05-14 |
2018-04-30 |
Astrazeneca Ab |
Fremgangsmåder til reducering af niveauer af basofile celler
|
US20090028857A1
(en)
*
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
JP5490714B2
(ja)
*
|
2007-11-28 |
2014-05-14 |
メディミューン,エルエルシー |
タンパク質製剤
|
WO2009076323A2
(en)
|
2007-12-06 |
2009-06-18 |
Genalyte Inc. |
Monitoring enzymatic process
|
WO2009082485A1
(en)
|
2007-12-26 |
2009-07-02 |
Vaccinex, Inc. |
Anti-c35 antibody combination therapies and methods
|
EP2260102A1
(en)
|
2008-03-25 |
2010-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
AU2009242453B2
(en)
|
2008-05-02 |
2014-12-04 |
Seagen Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
WO2009148896A2
(en)
|
2008-05-29 |
2009-12-10 |
Nuclea Biotechnologies, LLC |
Anti-phospho-akt antibodies
|
EP2315779A2
(en)
|
2008-07-09 |
2011-05-04 |
Biogen Idec MA Inc. |
Compositions comprising antibodies to lingo or fragments thereof
|
WO2010027818A2
(en)
|
2008-08-25 |
2010-03-11 |
Dana-Farber Cancer Institute, Inc. |
Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
|
US8192738B2
(en)
|
2008-09-19 |
2012-06-05 |
Medimmune, Llc |
Targeted antibodies directed to DLL4
|
WO2010062627A2
(en)
|
2008-10-27 |
2010-06-03 |
Genalyte Inc. |
Biosensors based on optical probing and sensing
|
CN102272154A
(zh)
|
2008-10-29 |
2011-12-07 |
惠氏有限责任公司 |
单域抗原结合性分子的纯化方法
|
CN104740631B
(zh)
|
2008-10-29 |
2019-04-16 |
阿布林克斯公司 |
单域抗原结合性分子的制剂
|
US8642280B2
(en)
|
2008-11-07 |
2014-02-04 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Teneurin and cancer
|
BRPI0921845A2
(pt)
|
2008-11-12 |
2019-09-17 |
Medimmune Llc |
formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
|
WO2010072740A2
(en)
|
2008-12-23 |
2010-07-01 |
Astrazeneca Ab |
TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
|
US20120003235A1
(en)
|
2008-12-31 |
2012-01-05 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
US8852608B2
(en)
|
2009-02-02 |
2014-10-07 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
WO2010093993A2
(en)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
CN102448494B
(zh)
|
2009-02-13 |
2016-02-03 |
免疫医疗公司 |
具有胞内可裂解的键的免疫共轭物
|
US20110311521A1
(en)
|
2009-03-06 |
2011-12-22 |
Pico Caroni |
Novel therapy for anxiety
|
EP2241323A1
(en)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W and brain cancers
|
UY32560A
(es)
|
2009-04-29 |
2010-11-30 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
JP6059013B2
(ja)
|
2009-05-08 |
2017-01-11 |
バクシネックス インコーポレーティッド |
抗cd100抗体およびこれを使用するための方法
|
MX2012001882A
(es)
|
2009-08-13 |
2012-04-11 |
Crucell Holland Bv |
Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
|
EP2292266A1
(en)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Treating cancer by modulating copine III
|
WO2011036118A1
(en)
|
2009-09-22 |
2011-03-31 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
WO2011041721A1
(en)
|
2009-10-02 |
2011-04-07 |
Biogen Idec Ma Inc. |
Methods of preventing and removing trisulfide bonds
|
CA2776385C
(en)
|
2009-10-07 |
2019-04-09 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
NZ628923A
(en)
|
2009-11-24 |
2016-02-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
CA2789629A1
(en)
|
2010-02-10 |
2011-08-18 |
Immunogen, Inc. |
Cd20 antibodies and uses thereof
|
EP2542578A1
(en)
|
2010-03-05 |
2013-01-09 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Smoc1, tenascin-c and brain cancers
|
US20130034543A1
(en)
|
2010-04-19 |
2013-02-07 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
Modulating xrn1
|
WO2011154485A1
(en)
|
2010-06-10 |
2011-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
SG186985A1
(en)
|
2010-07-09 |
2013-02-28 |
Crucell Holland Bv |
Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
CA2805572A1
(en)
|
2010-07-16 |
2012-01-19 |
Martin Hegen |
Modified single domain antigen binding molecules and uses thereof
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
JP6097690B2
(ja)
|
2010-09-02 |
2017-03-15 |
ヴァクシネックス, インコーポレイテッド |
抗cxcl13抗体およびそれを用いる方法
|
EP2614080A1
(en)
|
2010-09-10 |
2013-07-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Phosphorylated twist1 and metastasis
|
EP3581206A1
(en)
|
2010-10-22 |
2019-12-18 |
Seattle Genetics, Inc. |
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the p13k-akt mtor pathway
|
CA3060724A1
(en)
|
2010-11-05 |
2012-05-10 |
Genalyte, Inc. |
Optical analyte detection systems and methods of use
|
EP2635607B1
(en)
|
2010-11-05 |
2019-09-04 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
EP2640738A1
(en)
|
2010-11-15 |
2013-09-25 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Anti-fungal agents
|
AU2012237287B2
(en)
|
2011-03-30 |
2016-09-08 |
Ablynx Nv |
Methods of treating immune disorders with single domain antibodies against TNF-alpha
|
SG194567A1
(en)
|
2011-04-21 |
2013-12-30 |
Seattle Genetics Inc |
Novel binder-drug conjugates (adcs) and their use
|
US9562252B2
(en)
|
2011-05-13 |
2017-02-07 |
Biogen Ma Inc. |
Methods of preventing and removing trisulfide bonds
|
WO2012162561A2
(en)
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
EP2717911A1
(en)
|
2011-06-06 |
2014-04-16 |
Novartis Forschungsstiftung, Zweigniederlassung |
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
US9244074B2
(en)
|
2011-06-07 |
2016-01-26 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
EP2773373B1
(en)
|
2011-11-01 |
2018-08-22 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
CA2853951A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
US9221907B2
(en)
|
2011-11-01 |
2015-12-29 |
Bionomics Inc. |
Anti-GPR49 monoclonal antibodies
|
AU2012332590B2
(en)
|
2011-11-01 |
2016-10-20 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
KR102052774B1
(ko)
|
2011-11-04 |
2019-12-04 |
자임워크스 인코포레이티드 |
Fc 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
|
US20140314787A1
(en)
|
2011-11-08 |
2014-10-23 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Treatment for neurodegenerative diseases
|
US20140294732A1
(en)
|
2011-11-08 |
2014-10-02 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Early diagnostic of neurodegenerative diseases
|
RU2014128467A
(ru)
|
2011-12-14 |
2016-02-10 |
Сиэтл Дженетикс, Инк. |
Новые коньюгаты связывающее соединение-активное соединение (adc) и их применение
|
EP2800583A1
(en)
|
2012-01-02 |
2014-11-12 |
Novartis AG |
Cdcp1 and breast cancer
|
EP2812702B1
(en)
|
2012-02-10 |
2019-04-17 |
Seattle Genetics, Inc. |
Diagnosis and management of CD30-expressing cancers
|
AU2013225812B2
(en)
|
2012-03-02 |
2017-11-30 |
Vaccinex, Inc. |
Methods for the treatment of B cell-mediated inflammatory diseases
|
EP2825885B1
(en)
|
2012-03-12 |
2021-05-12 |
The Board of Trustees of the University of Illinois |
Optical analyte detection systems with magnetic enhancement
|
WO2013144240A1
(en)
|
2012-03-29 |
2013-10-03 |
Friedrich Miescher Institute For Biomedical Research |
Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
WO2013169693A1
(en)
|
2012-05-09 |
2013-11-14 |
Bristol-Myers Squibb Company |
Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
|
EP2847230B1
(en)
|
2012-05-10 |
2020-08-12 |
Zymeworks Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
|
BR112014028306A2
(pt)
|
2012-05-15 |
2018-04-17 |
Morphotek, Inc. |
métodos para tratamento de câncer gástrico.
|
JP5868549B2
(ja)
|
2012-05-24 |
2016-02-24 |
マウントゲイト グループ リミテッド |
狂犬病感染の予防および治療に関する組成物および方法
|
EP2866831A1
(en)
|
2012-06-29 |
2015-05-06 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating diseases by modulating a specific isoform of mkl1
|
EP2870242A1
(en)
|
2012-07-05 |
2015-05-13 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
WO2014006115A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
|
MY181648A
(en)
|
2012-08-24 |
2020-12-30 |
Univ California |
Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
|
LT2900277T
(lt)
|
2012-12-13 |
2022-04-11 |
Immunomedics, Inc. |
Antikūnų ir sn-38 imunokonjugatų dozės, skirtos pagerintam veiksmingumui ir sumažintam toksiškumui
|
US20150376597A1
(en)
|
2013-02-08 |
2015-12-31 |
Friedrich Miescher Institute For Biomedical Research (Fmi) |
Novel methods for the targeted introduction of viruses into cells
|
AU2013205589A1
(en)
|
2013-03-08 |
2014-09-25 |
Vaccinex, Inc. |
Anti-CXCL13 antibodies and associated epitope sequences
|
CA2907181C
(en)
|
2013-03-15 |
2023-10-17 |
Viktor Roschke |
Multivalent and monovalent multispecific complexes and their uses
|
US9983206B2
(en)
|
2013-03-15 |
2018-05-29 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions for enhancing immunoassays
|
SG10201800800YA
(en)
|
2013-05-06 |
2018-03-28 |
Scholar Rock Inc |
Compositions and methods for growth factor modulation
|
WO2015019286A1
(en)
|
2013-08-07 |
2015-02-12 |
Friedrich Miescher Institute For Biomedical Research |
New screening method for the treatment friedreich's ataxia
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
EP3063317B1
(en)
|
2013-10-28 |
2020-06-03 |
DOTS Technology Corp. |
Allergen detection
|
JP6525474B2
(ja)
|
2013-12-06 |
2019-06-05 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
オーロラキナーゼ阻害剤と抗cd30抗体の併用
|
JP6721507B2
(ja)
|
2013-12-23 |
2020-07-15 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
Ksp阻害剤との抗体薬物複合体(adc)
|
EP3126397B1
(en)
|
2014-04-04 |
2020-01-29 |
Bionomics, Inc. |
Humanized antibodies that bind lgr5
|
CN106456784A
(zh)
|
2014-04-16 |
2017-02-22 |
拜康有限公司 |
包含摩尔过量的山梨醇的稳定蛋白质制剂
|
EP3888690A3
(en)
|
2014-05-16 |
2021-10-20 |
MedImmune, LLC |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
EP3154579A1
(en)
|
2014-06-13 |
2017-04-19 |
Friedrich Miescher Institute for Biomedical Research |
New treatment against influenza virus
|
AU2015280436A1
(en)
|
2014-06-23 |
2017-02-02 |
Bionomics, Inc. |
Antibodies that bind LGR4
|
US10308935B2
(en)
|
2014-06-23 |
2019-06-04 |
Friedrich Miescher Institute For Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
|
WO2015200260A1
(en)
|
2014-06-24 |
2015-12-30 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
US20170165261A1
(en)
|
2014-07-01 |
2017-06-15 |
Brian Arthur Hemmings |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
WO2016029079A2
(en)
|
2014-08-21 |
2016-02-25 |
Walter Reed Army Institute Of Research Department Of The Army |
Monoclonal antibodies for treatment of microbial infections
|
EP3197557A1
(en)
|
2014-09-24 |
2017-08-02 |
Friedrich Miescher Institute for Biomedical Research |
Lats and breast cancer
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
HUE061672T2
(hu)
|
2014-11-12 |
2023-08-28 |
Seagen Inc |
Glikán-interakcióban lévõ vegyületek és felhasználási módszerek
|
ES2832802T3
(es)
|
2014-11-21 |
2021-06-11 |
Univ Maryland |
Sistemas de administración dirigida del particulado específico de una estructura
|
US10485880B2
(en)
|
2014-12-15 |
2019-11-26 |
Bayer Pharma Aktiengesellschaft |
Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodies
|
BR112017020955A2
(pt)
|
2015-03-31 |
2018-07-10 |
Medimmune Limited |
forma de il33, formas mutadas de il33, anticorpos, ensaios e métodos de uso dos mesmos
|
WO2016207089A1
(de)
|
2015-06-22 |
2016-12-29 |
Bayer Pharma Aktiengesellschaft |
Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen
|
CA2990394A1
(en)
|
2015-06-23 |
2016-12-29 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies
|
CN108025086A
(zh)
|
2015-06-23 |
2018-05-11 |
拜耳制药股份公司 |
Ksp抑制剂与抗b7h3抗体的抗体-活性物质缀合物(adc)
|
KR20180020225A
(ko)
|
2015-06-23 |
2018-02-27 |
바이엘 파마 악티엔게젤샤프트 |
Ksp 억제제의 표적화된 접합체
|
EP3316885B1
(en)
|
2015-07-01 |
2021-06-23 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
JP2018528191A
(ja)
|
2015-08-19 |
2018-09-27 |
ラトガーズ, ザ ステイト ユニバーシティ オブ ニュー ジャージー |
抗体を生成する新規な方法
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
EP3368566A1
(en)
|
2015-10-28 |
2018-09-05 |
Friedrich Miescher Institute for Biomedical Research |
Tenascin-w and biliary tract cancers
|
AU2016353153B2
(en)
|
2015-11-12 |
2023-11-23 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
JP2019509322A
(ja)
|
2016-03-22 |
2019-04-04 |
バイオノミクス リミテッド |
抗lgr5モノクローナル抗体の投与
|
CN116059390A
(zh)
|
2016-03-24 |
2023-05-05 |
拜耳制药股份公司 |
具有酶促可裂解基团的细胞毒性活性物质的前药
|
WO2017216028A1
(en)
|
2016-06-15 |
2017-12-21 |
Bayer Pharma Aktiengesellschaft |
Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
|
WO2018027124A1
(en)
|
2016-08-05 |
2018-02-08 |
Medimmune, Llc |
Anti-o2 antibodies and uses thereof
|
IL265274B2
(en)
|
2016-09-16 |
2023-11-01 |
Bionomics Ltd |
A combination of an antibody against LGR5 and an antibody that inhibits PD-1 for the treatment of tumors
|
WO2018075375A1
(en)
|
2016-10-19 |
2018-04-26 |
Medimmune, Llc |
Anti-o1 antibodies and uses thereof
|
EP3541847A4
(en)
|
2016-11-17 |
2020-07-08 |
Seattle Genetics, Inc. |
COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
|
EP3551225A1
(en)
|
2016-12-07 |
2019-10-16 |
Agenus Inc. |
Antibodies and methods of use thereof
|
IL291308B2
(en)
|
2016-12-21 |
2024-07-01 |
Bayer Pharma AG |
Drug-antibody conjugates with enzymatically cleavable groups
|
CA3047522A1
(en)
|
2016-12-21 |
2018-06-28 |
Bayer Pharma Aktiengesellschaft |
Specific antibody drug conjugates (adcs) having ksp inhibitors
|
EP3558386A1
(de)
|
2016-12-21 |
2019-10-30 |
Bayer Aktiengesellschaft |
Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
|
WO2018129029A1
(en)
|
2017-01-04 |
2018-07-12 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
EP3589319A4
(en)
|
2017-03-03 |
2021-07-14 |
Seagen Inc. |
COMPOUNDS INTERACTING WITH GLYCAN AND METHODS OF USE
|
US11203629B2
(en)
|
2017-04-22 |
2021-12-21 |
Immunomic Therapeutics, Inc. |
LAMP constructs
|
BR112019023014A2
(pt)
|
2017-05-02 |
2020-05-19 |
Immunomic Therapeutics Inc |
constructos de lamp aperfeiçoados compreendendo antígenos de câncer
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
US11655307B2
(en)
|
2017-05-30 |
2023-05-23 |
The Board Of Regents Of The University Of Oklahoma |
Anti-doublecortin-like kinase 1 antibodies and methods of use
|
TWI728250B
(zh)
|
2017-06-21 |
2021-05-21 |
美商基利科學股份有限公司 |
靶向hiv gp120及cd3之多特異性抗體
|
WO2019035001A1
(en)
|
2017-08-18 |
2019-02-21 |
Friedrich Miescher Institute For Biomedical Research |
NEW METHODS FOR TARGETED INTRODUCTION OF VIRUSES IN CELLS AND TISSUES
|
TW201922281A
(zh)
|
2017-10-11 |
2019-06-16 |
美商西雅圖遺傳學公司 |
降低抗cd30抗體藥物綴合物療法之副作用之方法
|
CN111630069B
(zh)
|
2017-10-13 |
2024-05-31 |
勃林格殷格翰国际有限公司 |
针对Thomsen-nouvelle(Tn)抗原的人抗体
|
WO2019089870A1
(en)
|
2017-11-01 |
2019-05-09 |
Seattle Genetics, Inc. |
Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
|
WO2019094595A2
(en)
|
2017-11-09 |
2019-05-16 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
CA3089754A1
(en)
|
2018-01-31 |
2019-08-08 |
Bayer Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
TW202003047A
(zh)
|
2018-03-23 |
2020-01-16 |
美商西雅圖遺傳學公司 |
包括微管蛋白破壞劑之抗體藥物結合物治療實體腫瘤之用途
|
CN112368020B
(zh)
|
2018-05-07 |
2024-05-31 |
展马博联合股份有限公司 |
抗pd-1抗体和抗组织因子抗体-药物偶联物组合治疗癌症的方法
|
MX2020011823A
(es)
|
2018-05-07 |
2021-03-29 |
Genmab As |
Metodos para tratar cancer con combinacion de anticuerpo anti-muerte programada-1 (pd-1) y conjugado de anticuerpo anti-factor de tejido y farmaco.
|
US20210261647A1
(en)
|
2018-05-15 |
2021-08-26 |
Immunomic Therapeutics, Inc |
Lamp constructs comprising allergens
|
BR112020025718A2
(pt)
|
2018-06-18 |
2021-04-06 |
Bayer Aktiengesellschaft |
Conjugados de ligante/agente ativo direcionados contra cxcr5, tendo aglutinantes enzimaticamente cliváveis e perfil de atividade melhorado
|
JP7126573B2
(ja)
|
2018-07-03 |
2022-08-26 |
ギリアード サイエンシーズ, インコーポレイテッド |
HIV gp120を標的化する抗体および使用方法
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
JP2022502508A
(ja)
|
2018-10-01 |
2022-01-11 |
シージェン・インコーポレーテッド |
抗cd30抗体薬物複合体療法を使用して末梢性t細胞リンパ腫を処置する方法
|
EP3873533A1
(en)
|
2018-10-30 |
2021-09-08 |
Genmab A/S |
Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate
|
MX2021009138A
(es)
|
2019-02-05 |
2021-09-10 |
Seagen Inc |
Anticuerpos anti-cd228 y conjugados de anticuerpo-farmaco.
|
EP3947442A2
(en)
|
2019-03-28 |
2022-02-09 |
Danisco US Inc. |
Engineered antibodies
|
WO2021013693A1
(en)
|
2019-07-23 |
2021-01-28 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
CA3150762A1
(en)
|
2019-08-12 |
2021-02-18 |
Aptevo Research And Development Llc |
4-1 bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1 bb, antibodies against ox40
|
KR20220069964A
(ko)
|
2019-09-25 |
2022-05-27 |
씨젠 인크. |
조혈암의 치료를 위한 항-cd30 adc, 항-pd-1 및 화학치료제 조합
|
WO2021067776A2
(en)
|
2019-10-04 |
2021-04-08 |
Seagen Inc. |
Anti-pd-l1 antibodies and antibody-drug conjugates
|
KR20220083773A
(ko)
|
2019-10-18 |
2022-06-20 |
이뮤노믹 쎄라퓨틱스, 인크. |
암 항원을 포함하는 개선된 lamp 구축물
|
IL292685A
(en)
|
2019-11-04 |
2022-07-01 |
Seagen Inc |
Anti-cd30 drug-antibody conjugates and their use in the treatment of HIV infection
|
US20230027495A1
(en)
|
2019-11-07 |
2023-01-26 |
Genmab A/S |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
TW202131954A
(zh)
|
2019-11-07 |
2021-09-01 |
丹麥商珍美寶股份有限公司 |
利用鉑類劑與抗組織因子抗體-藥物共軛體之組合來治療癌症之方法
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
CN114945409A
(zh)
|
2020-01-13 |
2022-08-26 |
新免疫技术有限公司 |
用il-7蛋白和双特异性抗体的组合治疗肿瘤的方法
|
IL295202A
(en)
|
2020-01-31 |
2022-10-01 |
Seagen Inc |
Anti-cd30 antibody-drug conjugates and their use for the treatment of non-Hodgkin's lymphoma
|
AU2021273256A1
(en)
|
2020-05-13 |
2022-12-15 |
Seagen Inc. |
Methods of treating cancer using a combination of anti-CD30 antibody-drug conjugates
|
CN116568337A
(zh)
|
2020-08-04 |
2023-08-08 |
思进股份有限公司 |
抗cd228抗体和抗体-药物缀合物
|
CA3192526A1
(en)
|
2020-09-04 |
2022-03-10 |
Rutgers, The State University Of New Jersey |
Sars-cov-2 vaccines and antibodies
|
US20230382978A1
(en)
|
2020-10-15 |
2023-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
JP2023549581A
(ja)
|
2020-11-17 |
2023-11-27 |
シージェン インコーポレイテッド |
ツカチニブ及び抗pd-1/抗pd-l1抗体の組み合わせによりがんを治療する方法
|
EP4255574A1
(en)
|
2020-12-01 |
2023-10-11 |
Aptevo Research and Development LLC |
Heterodimeric psma and cd3-binding bispecific antibodies
|
WO2022153194A1
(en)
|
2021-01-13 |
2022-07-21 |
Memorial Sloan Kettering Cancer Center |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
US20240115721A1
(en)
|
2021-01-13 |
2024-04-11 |
Memorial Sloan Kettering Cancer Center |
Anti-dll3 antibody-drug conjugate
|
EP4348263A1
(en)
|
2021-05-28 |
2024-04-10 |
Alexion Pharmaceuticals, Inc. |
Methods for detecting cm-tma biomarkers
|
CA3218481A1
(en)
|
2021-06-14 |
2022-12-22 |
argenx BV |
Anti-il-9 antibodies and methods of use thereof
|
WO2023278377A1
(en)
|
2021-06-29 |
2023-01-05 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
KR20240046323A
(ko)
|
2021-07-13 |
2024-04-08 |
비온테크 에스이 |
암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제
|
CA3234647A1
(en)
|
2021-10-06 |
2023-04-13 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 in combination therapy
|
AU2022377628A1
(en)
|
2021-10-29 |
2024-04-11 |
Seagen Inc. |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
WO2023192436A1
(en)
|
2022-03-31 |
2023-10-05 |
Alexion Pharmaceuticals, Inc. |
Singleplex or multiplexed assay for complement markers in fresh biological samples
|
WO2023201201A1
(en)
|
2022-04-10 |
2023-10-19 |
Immunomic Therapeutics, Inc. |
Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
|
TW202408583A
(zh)
|
2022-05-06 |
2024-03-01 |
丹麥商珍美寶股份有限公司 |
使用抗組織因子抗體-藥物共軛體以治療癌症之方法
|
WO2024054436A1
(en)
|
2022-09-06 |
2024-03-14 |
Alexion Pharmaceuticals, Inc. |
Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
|
WO2024097816A1
(en)
|
2022-11-03 |
2024-05-10 |
Seagen Inc. |
Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer
|
US20240226313A1
(en)
|
2022-11-17 |
2024-07-11 |
Sanofi |
Ceacam5 antibody-drug conjugates and methods of use thereof
|
WO2024105205A1
(en)
|
2022-11-17 |
2024-05-23 |
Bayer Aktiengesellschaft |
Antibody-drug conjugates (a2dcs) with enzymatically cleavable groups
|
WO2024115725A1
(en)
|
2022-12-01 |
2024-06-06 |
BioNTech SE |
Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
|